The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
670m shares in issue 1% holding in company = 6.7m shares, 0.8% I rounded up.
Doh, having now read the RNs properly I understand. More shares in issue.
So if my arithmetic is correct, CF reduced his holding by 0.8% equal to 5m shares.
Not quite sure how he still holds the same amount of shares though.
There's nothing like a good old positive RNS to generate a wave of sells. 30:1 sells v buys according to LSE printouts. The usual games methinks.
Appreciate the devil is in the detail, but if I understood correctly what J Hunt said yesterday regarding life sciences and R&D, for uk based companies that spend £2m or more on developing groundbreaking remedies for diseases and ailments like cancer, rsv, malaria, there would be £500k of gov funding available.
Hopefully some of the work Poolbeg are doing will qualify for said grants.
Story of my life, added a 100k at 20p last week :-(
Method to be adopted for shareholder distribution, to be defined during year end accounts presentation. Doubt you will see any dividend until after the 2023 half year report.
Rainbow chasers cashing out and moving across to Polb.
Thats all well & good, but Vechain and WL are only supposed to account for 20% of Syme's revenues. As someone who claims to "understand it all" maybe you could enlighten us on where the other 80% of expected revenues and contracts are coming from. By the time the Italian government gets its act together Syme will probably need another loan.
Should have added the new information came from the BdD, who gave an insight into the steps to outlicensing and partnerships. Basically 9 to 12 months away.
Words you never see posted, "my sell was printed as a buy"
Sorry 500k sold.
2m bought, 50k sold, red finish never in doubt :-)